168 related articles for article (PubMed ID: 37699023)
21. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
22. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
[TBL] [Abstract][Full Text] [Related]
23. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
Li W; Li N; Kang X; Shi K
Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of lncRNA HOTAIR as a biomarker for detecting and staging of non-small cell lung cancer.
Yao X; Wang T; Sun MY; Yuming Y; Guixin D; Liu J
Biomarkers; 2022 Sep; 27(6):526-533. PubMed ID: 35959801
[No Abstract] [Full Text] [Related]
25. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
26. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
27. Identification and Validation of Serum CST1 as a Diagnostic Marker for Differentiating Early-Stage Non-Small Cell Lung Cancer from Pulmonary Benign Nodules.
Lai Y; Wang Y; Wu Y; Wu M; Xing S; Xie Y; Chen S; Li X; Zhang A; He Y; Li H; Dai S; Wang J; Lin S; Bai Y; Du H; Liu W
Cancer Control; 2022; 29():10732748221104661. PubMed ID: 35653624
[TBL] [Abstract][Full Text] [Related]
28. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
29. Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer.
Xiong L; Zhu C; Lu Y; Chen M; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15671-15677. PubMed ID: 37658862
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
31. RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer.
Yang Y; Lin J; Guo S; Xue X; Wang Y; Qiu S; Cui J; Ma L; Zhang X; Wang J
Cancer Cell Int; 2020 Dec; 20(1):587. PubMed ID: 33372599
[TBL] [Abstract][Full Text] [Related]
32. Circulating TP73-AS1 and CRNDE serve as diagnostic and prognostic biomarkers for non-small cell lung cancer.
Yuan RX; Dai CH; Chen P; Lv MJ; Shu Y; Wang ZP; Xu YP; Li J
Cancer Med; 2023 Jan; 12(2):1655-1672. PubMed ID: 35871358
[TBL] [Abstract][Full Text] [Related]
33. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
34. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
36. Increased serum exosomal long non-coding RNA SNHG15 expression predicts poor prognosis in non-small cell lung cancer.
Han P; Zhao J; Gao L
J Clin Lab Anal; 2021 Nov; 35(11):e23979. PubMed ID: 34551140
[TBL] [Abstract][Full Text] [Related]
37. CircFOXP1: A novel serum diagnostic biomarker for non-small cell lung cancer.
Luo Y; Zhang Q; Lv B; Shang Y; Li J; Yang L; Yu Z; Luo K; Deng X; Min L; Zhu T
Int J Biol Markers; 2022 Mar; 37(1):58-65. PubMed ID: 35072545
[TBL] [Abstract][Full Text] [Related]
38. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic potential of a circRNA-miRNA network in non-small cell lung cancer.
Ma X; Lou C; Pan J; Zhou C; Zhao X; Li N; Tian H; Meng X
J Mol Med (Berl); 2023 Jun; 101(6):671-684. PubMed ID: 37069371
[TBL] [Abstract][Full Text] [Related]
40. Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer.
Liang N; Zhang X; Zhang L; Jiang M; Bai H; Ding C; Cai Y; Zhou C; Han Y; Gong Z
Oncology; 2023; 101(8):527-536. PubMed ID: 37307805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
